

**MOL #64568**

**Delineating the mode of action of adenosine A<sub>1</sub> receptor allosteric  
modulators**

**Celine Valant, Luigi Aurelio, Vijay B. Urmaliya, Paul White, Peter J. Scammells,  
Patrick M. Sexton and Arthur Christopoulos**

Drug Discovery Biology & Department of Pharmacology (CV, PMS, AC); Medicinal  
Chemistry and Drug Action (LA, VBU, PW, PJS), Monash Institute of  
Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

**MOL #64568**

**Running title:** Dual mode of action of adenosine A<sub>1</sub> allosteric modulators

**Corresponding author:**

Prof. Arthur Christopoulos, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria, Australia, 3052. Tel: +61 3 9903 9067. Fax: +613 9903 9581.

Email: [arthur.christopoulos@med.monash.edu.au](mailto:arthur.christopoulos@med.monash.edu.au)

**Text pages:** 38

**Tables:** 3

**Figures:** 8

**References:** 38

**Abstract** (words): 209

**Introduction** (words): 750

**Discussion** (words): 1433

**Abbreviations:** 2A3BT, 2-amino-3-benzoylthiophenes; ADA, adenosine deaminase; ATCM, allosteric ternary complex model; [<sup>3</sup>H]CCPA, 2-Chloro-N<sup>6</sup>-[<sup>3</sup>H]cyclopentyladenosine; CHO, Chinese hamster ovary; DMEM, Dulbecco's modified Eagle medium; [<sup>3</sup>H]DPCPX, [<sup>3</sup>H]8-Cyclopentyl-1,3-dipropylxanthine; FBS, fetal bovine serum; GPCR, G protein-coupled receptor; Gpp(NH)p, 5'-guanylyl-imidodiphosphate; [<sup>35</sup>S]GTPγS, [<sup>35</sup>S] guanosine 5'-O-[γ-thio]triphosphate LUF5484, 2-amino-(4,5,6,7-tetrahydrobenzo[*b*]thiophen-3-yl)(3,4-dichlorophenyl)methanone; PD81,723, 2-amino-4,5-dimethyl-3-thienyl-[3-(trifluoromethyl)phenyl]methanone; *R*-PIA, (–)-N<sup>6</sup>-(2-Phenylisopropyl)adenosine; T62, 2-amino-(4,5,6,7-tetrahydrobenzo[*b*]thiophen-3-yl)(4-chlorophenyl)methanone; VCP333, *tert*-butyl 2-amino-3-(4-chlorobenzoyl)-7,8-dihydro-4*H*-thieno[2,3-*d*]azepine-6(5*H*)-carboxylate; VCP520, 2-amino-4-(3,5-bis(trifluoromethyl)phenyl)thiophen-3-yl(phenyl)methanone.

**MOL #64568**

**ABSTRACT**

Despite the identification of 2-amino-3-benzoylthiophenes (2A3BTs) as the first example of small molecule allosteric potentiators of agonist function at a G protein-coupled receptor (GPCR) — the adenosine A<sub>1</sub> receptor — their mechanism of action is still not fully understood. We now report the mechanistic basis for the complex behaviors noted for 2A3BTs at A<sub>1</sub> receptors. Using a combination of membrane-based and intact-cell radioligand binding, multiple signaling assays, and a native tissue bioassay, we found that the allosteric interaction between 2A3BTs and the agonists, 2-Chloro-N<sup>6</sup>-[<sup>3</sup>H]cyclopentyladenosine ([<sup>3</sup>H]CCPA) or (–)-N<sup>6</sup>-(2-Phenylisopropyl)adenosine (*R*-PIA), or the antagonist, [<sup>3</sup>H]8-Cyclopentyl-1,3-dipropylxanthine ([<sup>3</sup>H]DPCPX), is consistent with a ternary complex model involving recognition of a single extracellular allosteric site. However, when allowed access to the intracellular milieu, 2A3BTs have a secondary action as direct G protein inhibitors; this latter property is receptor-independent as it is observed in non-transfected cells and also after stimulation of another GPCR. In addition, we found that 2A3BTs can signal as allosteric agonists in their own right but show bias towards certain pathways relative to the orthosteric agonist, *R*-PIA. These results indicate that 2A3BTs have a dual mode of action when interacting with the A<sub>1</sub> receptor and that they can engender novel functional selectivity in A<sub>1</sub> signaling. These mechanisms need to be factored into allosteric ligand structure-activity studies.

## **INTRODUCTION**

G protein-coupled receptors (GPCRs) are the largest family of cell surface proteins (Lagerstrom and Schioth, 2008) and remain pre-eminent targets for novel drug discovery (Overington et al., 2006). An important paradigm of drug action at GPCRs is the recognition that most of these receptors possess at least one allosteric site that is topographically distinct from the orthosteric site that binds the endogenous agonist (Christopoulos, 2002; Christopoulos and Kenakin, 2002). Upon binding, allosteric ligands modulate the conformation of the GPCR and, therefore, the biological properties of co-bound orthosteric ligands, either by changing their affinities, their signaling efficacies, or both (May et al., 2007b). More recently, it has been suggested that allosteric modulators can also engender functional selectivity in the signaling of orthosteric ligands, that is, the allosteric ligand may 'bias' the stimulus imparted by the orthosteric ligand such that only a subset of the possible repertoire of intracellular signaling cascades linked to the GPCR are activated (Leach et al., 2007). Thus, understanding the mechanisms of action of GPCR allosteric modulators offers potential for the development of novel tools with which to probe receptor function, as well as more selective therapeutic agents (Conn et al., 2009).

The A<sub>1</sub> receptor, one of four subtypes of GPCR for the purine nucleoside, adenosine, was the first GPCR for which positive allosteric modulators of agonist function were described (Bruns and Fergus, 1990; Bruns et al., 1990). The finding that 2A3BT derivatives, exemplified by compounds such as 2-amino-(4,5,6,7-tetrahydrobenzo[*b*]thiophen-3-yl)(4-chlorophenyl)methanone (T62), 2-amino-4,5-dimethyl-3-thienyl-[3-(trifluoromethyl)phenyl]methanone (PD81,723) and 2-amino-(4,5,6,7-tetrahydrobenzo[*b*]thiophen-3-yl)(3,4-dichlorophenyl)methanone (LUF5484) (Figure 1),

**MOL #64568**

potentiated the actions of adenosine was very promising, and opened a new avenue of promoting selective activation of the A<sub>1</sub> receptor by its endogenous agonist. Moreover, extracellular adenosine concentrations can quickly rise up to 100-fold over basal levels in response to cellular damage in inflammatory or ischemic tissues (Latini et al., 1999; Rudolphi et al., 1992), providing a rationale for both spatial (tissue-specific) and temporal selectivity of drug action via targeting allosteric sites on adenosine receptors; potentiation of the activity of A<sub>1</sub> receptors has been implicated in the treatment of conditions such as ischemia reperfusion injury, paroxysmal supraventricular tachycardia, chronic pain, and non-insulin-dependent diabetes mellitus (Elzein and Zablocki, 2008; Gao and Jacobson, 2007).

Despite the early identification of 2A3BTs as allosteric modulators of A<sub>1</sub> receptors, their mechanism of action appears complex and is not fully understood. For instance, when tested against agonist radioligands in equilibrium assays, these modulators typically yield bell-shaped binding curves, characterized by an increase in orthosteric radioligand binding at low modulator concentrations and a decrease in orthosteric binding at high concentrations; similar experiments using antagonist radioligands only reveal inhibition of orthosteric binding by the modulator. This property has been almost invariably interpreted as evidence that 2A3BTs recognize an allosteric site at low concentrations but also bind to the orthosteric site at high concentrations. Within such a scheme, the interaction with agonists presumably reflects a mixed mode of positive cooperativity and competitive inhibition, whereas the interaction with antagonists reflects both negative cooperativity and competition. Accordingly, many structure-activity relationships have been performed in order to separate the “allosteric component” from the “orthosteric component” of these ligands (Aurelio et al., 2008; Aurelio et al., 2009; Baraldi et al., 2000; Ferguson et al., 2008; Figler et al., 2003; Lutjens et al., 2003; Nikolakopoulos et al., 2006; van der Klein et al., 1999). Although these studies have

**MOL #64568**

yielded ligands with increased allosteric potencies, none have successfully moved away from the 2-aminothiophene scaffold, nor have they been able to completely eradicate the apparently orthosteric/competitive component of their actions. In order to delineate the basis of this phenomenon, we undertook a detailed study of the binding and functional properties of three 2A3BTs, the “prototypical” allosteric A<sub>1</sub> modulator, T62 (Baraldi et al., 2007; Baraldi et al., 2006; Bruns and Fergus, 1990; Childers et al., 2005), and two novel derivatives, 2-amino-4-(3,5-bis(trifluoromethyl)phenyl)thiophen-3-yl(phenyl)methanone (VCP520) and *tert*-butyl 2-amino-3-(4-chlorobenzoyl)-7,8-dihydro-4*H*-thieno[2,3-*d*]azepine-6(5*H*)-carboxylate (VCP333) (Figure 1) (Aurelio et al., 2009). We show that the divergent effects on agonist and antagonist binding affinities at low concentrations of 2A3BTs can be mechanistically accommodated by interaction with a common allosteric site, without the need to invoke an orthosteric component in the modulator actions; we reveal that these ligands can exhibit novel functional selectivity in their own right as allosteric agonists; we find that the inhibitory effects noted at high concentrations of 2A3BTs actually reflect a receptor-independent inhibition of G<sub>i/o</sub> protein activity. This dual mechanism of action of 2A3BTs as allosteric ligands of the A<sub>1</sub> receptor has significant implications for structure-activity studies of allosterism at this important GPCR family.

## MOL #64568

### MATERIALS AND METHODS

#### Synthesis of 2-amino-3-benzoylthiophene derivatives

T62 and VCP520 were synthesized as described previously (Aurelio et al., 2009; Nakanishi et al., 1973). The synthesis of VCP333 is described in the Supplementary Material.

#### Materials

Dulbecco's modified Eagle medium (DMEM) and hygromycin B were purchased from Invitrogen (Carlsbad, CA, U.S.A.). Foetal bovine serum (FBS) was purchased from ThermoTrace (Melbourne, VIC, Australia). 2-Chloro-N<sup>6</sup>-[<sup>3</sup>H]cyclopentyladenosine ([<sup>3</sup>H]CCPA) (42.6 Ci.mmol<sup>-1</sup>) and [<sup>3</sup>H]8-Cyclopentyl-1,3-dipropylxanthine ([<sup>3</sup>H]DPCPX) (120 Ci.mmol<sup>-1</sup>) were purchased from Perkin-Elmer (Boston, MA, U.S.A.) and adenosine deaminase (ADA), derived from calf intestine, was purchased from Roche (Basel, Switzerland). [<sup>35</sup>S]GTPγS (>1000 Ci/mmol) was purchased from both PerkinElmer Life Sciences and Amersham Biosciences. The *Sure-Fire*<sup>TM</sup> cellular ERK1/2 assay kits were a generous gift from TGR BioSciences (Adelaide, Australia). AlphaScreen<sup>TM</sup> reagents for ERK1/2 and cAMP assays were from PerkinElmer Life Sciences. Ultima gold scintillation cocktail was purchased from Packard Bioscience (Meriden, CT, U.S.A.). All other reagents were purchased from Sigma-Aldrich (St Louis, MO, U.S.A.).

#### Cell culture and membrane preparation

FlpIn Chinese hamster ovary (CHO) cells stably expressing adenosine A<sub>1</sub> receptors were generated and cultured as described previously (Stewart et al., 2009). FlpIn-CHO cells stably expressing muscarinic M<sub>2</sub> receptors (M<sub>2</sub> mAChR FlpIn-CHO; (May et al., 2007a)) were cultured as described for A<sub>1</sub> receptor FlpIn-CHO cells. Membranes of A<sub>1</sub> receptor and M<sub>2</sub>

## MOL #64568

mAChR were generated as described previously in Stewart et al. (Stewart et al., 2009), and May et al. (May et al., 2005), respectively.

### **Agonist and antagonist radioligand equilibrium binding assays**

Radioligand binding assays were performed using two different radioligands. When using [<sup>3</sup>H]CCPA (2nM), assays were performed as described previously (Ferguson et al., 2008), with the exception that membrane-based binding assays were at 30°C. When using [<sup>3</sup>H]DPCPX (1nM), assays were also performed as described previously (May et al., 2005), with the exception that membrane-based binding assays were at 30°C. These experiments were performed in the absence of guanine nucleotides in the case of agonist radioligand and antagonist radioligand whole cell binding, or in presence of 100 μM Gpp(NH)p in the case of antagonist radioligand membrane preparation binding. Non-specific binding was defined using 100μM R-PIA.

### **Dissociation kinetic binding assays**

Membrane homogenates (15 μg) were equilibrated with [<sup>3</sup>H]CCPA (2nM) in a 1ml total volume of assay buffer for 90 min at 30 °C. R-PIA (10μM), alone or in the presence of T62, VCP520 or VCP333, was then added at various time points to prevent the reassociation of [<sup>3</sup>H]CCPA with the receptor. In subsequent experiments designed to investigate the effect of a range of modulator concentrations on [<sup>3</sup>H]CCPA dissociation rate, a “two-point kinetic” experimental paradigm was used where the effect of increasing concentrations of allosteric ligand on [<sup>3</sup>H]CCPA dissociation was determined at 20 and 90 min. This approach is valid to determine [<sup>3</sup>H]CCPA dissociation rate constants if the full time course of radioligand dissociation is monophasic both in the absence and presence of modulator (Kostenis and



## MOL #64568

Mohr, 1996; Lazareno and Birdsall, 1995); this was the case in our current study. Incubation was terminated as described previously.

### Signaling assays

Interaction studies in ERK1/2 phosphorylation assays and [<sup>35</sup>S]GTPγS binding assays were performed as per Aurelio et al. (Aurelio et al., 2009). For ERK1/2 phosphorylation experiments, 3% (v/v) FBS was used as a positive control, and vehicle controls were also performed; data were normalized to the maximal response elicited by 3% (v/v) FBS at 6 min time point, unless otherwise specified. For either A<sub>1</sub> receptor or M<sub>2</sub> mAChR [<sup>35</sup>S]GTPγS binding assays, identical buffer and condition of incubation were used; data were normalized to the maximal response elicited by 1μM of *R*-PIA for interaction studies or to the fold over basal when experiments were performed at the M<sub>2</sub> mAChR. Calcium mobilization assays and cAMP assays were performed as described previously in Stewart et al. (Stewart et al., 2009).

### Isolated rat atria

Experiments were carried out in accordance with the Australian National Health and Medical Research Council Code of Practice (1997) under a protocol approved by the Institutional Animal Ethics Committee. Sprague Dawley rats (250-300g), were housed in North Kent Plastics (Animal Resources Center) cages with sawdust bedding and maintained on a constant 12-h light/dark cycle at 18-22°C. Animals were given normal tap water and food in the form of Clark King ARM cubes (Animal Resources Center) ad libitum. Rats were sacrificed by stunning followed by exsanguination, and hearts were rapidly removed and placed in Krebs-Henseleit solution (118mM NaCl; 4.7mM KCl; 1.2mM KH<sub>2</sub>PO<sub>4</sub>; 25mM NaHCO<sub>3</sub>; 11.7mM glucose; 1.1mM MgSO<sub>4</sub>; 2.5mM CaCl<sub>2</sub>). The right atrium was isolated and mounted in an organ bath at 37 °C, bubbled with 5% CO<sub>2</sub> / 95% O<sub>2</sub>, and allowed to contract spontaneously.

## MOL #64568

The rate of atrial contraction was measured using a force-transducer connected to a PowerLab data acquisition system (AD instruments, Australia). Responses to a low (10 nM; approx. EC<sub>10</sub>) concentration of *R*-PIA were determined in the presence of allosteric modulator (0.3 μM and 3 μM) or vehicle (0.1% DMSO). The modulator or vehicle was added 1 minute prior to *R*-PIA stimulation, and the magnitude of the resultant decrease in heart rate determined at the point of peak response, usually 2-3 minutes after addition of the *R*-PIA.

### Data analysis

Computerized nonlinear regression was performed using Prism 5.01 or a pre-release version of Prism 6.0 (GraphPad Software, San Diego, CA). Radioligand inhibition binding data were empirically fitted to a one-site inhibition mass action curve to determine inhibitor potency estimates, which were then converted to K<sub>i</sub> values as appropriate (Cheng and Prusoff, 1973). Radioligand potentiation binding curves were fitted to a simple allosteric ternary complex model to derive estimates of allosteric modulator affinity (K<sub>B</sub>) and cooperativity ( $\alpha$ ), the latter parameter being a measure of the strength and direction of the interaction between the orthosteric and allosteric sites (Christopoulos and Kenakin, 2002; May et al., 2007b); values of  $\alpha > 1$  denote positive cooperativity, whereas values of  $0 < \alpha < 1$  denote negative cooperativity. Dissociation kinetic data were fitted to monoexponential functions to derive observed dissociation rate constants. Where appropriate concentration-response curves were fitted to a three-parameter logistic equation to derive ligand potency estimates. Finally for whole cell functional ligand combination studies, the interaction between the orthosteric agonist, *R*-PIA, and the allosteric ligands T62, VCP520 or VCP333 was fitted to the following two forms of an operational model of allosterism and agonism (Aurelio et al., 2009; Leach et al., 2007) to derive functional estimates of modulator affinity, cooperativity and efficacy:

**MOL #64568**

$$E = \text{Basal} + \frac{(E_m - \text{Basal}) \left( \tau_A [A] (K_B + \alpha \beta [B]) + \tau_B [B] K_A \right)^n}{\left( [A] K_B + K_A K_B + K_A [B] + \alpha [A] [B] \right)^n + \left( \tau_A [A] (K_B + \alpha \beta [B]) + \tau_B [B] K_A \right)^n}$$

(Equation 1)

$$E = \text{Basal} + \frac{(E_m - \text{Basal}) \left( [A] (K_B + \alpha \beta [B]) + \tau_B [B] [EC_{50}] \right)^n}{[EC_{50}]^n (K_B + [B])^n + \left( [A] (K_B + \alpha \beta [B]) + \tau_B [B] [EC_{50}] \right)^n}$$

(Equation 2)

where  $E_m$  is the maximum attainable system response for the pathway under investigation,  $[A]$  and  $[B]$  are the concentrations of orthosteric agonist and allosteric modulator/agonist, respectively,  $K_B$  is the dissociation constant of the allosteric modulator,  $EC_{50}$  is the concentration of orthosteric (full) agonist yielding 50% of the response between minimal and maximal receptor activation in the absence of allosteric ligand,  $n$  is a transducer slope factor linking occupancy to response,  $\alpha$  and  $\beta$  are the cooperativity factors governing allosteric effects of the modulator on orthosteric agonist binding affinity and signaling efficacy, respectively, and  $\tau_A$  and  $\tau_B$  are operational measure of the ligands' respective signaling efficacies that incorporate receptor expression levels and efficiency of stimulus-response coupling (Aurelio et al., 2009; Leach et al., 2007). For this analysis, the entire family of curves for a given agonist-modulator combination across three different signaling pathways (ERK1/2 phosphorylation,  $Ca^{2+}$  mobilization and inhibition of cAMP accumulation) were globally fitted to the model;  $Ca^{2+}$  data were fitted to equation 1, whereas ERK1/2 and cAMP data were fitted to equation 2, with the  $pK_B$  parameter constrained to be shared across the entire family of curves.

All affinities, potencies, efficacies, and cooperativity parameters were estimated as logarithms (Christopoulos, 1998). Results are expressed as means  $\pm$  S.E. unless otherwise

**MOL #64568**

stated. Statistical analyses were by Student's *t*-test, or one-way ANOVA followed by Bonferroni's post-test, as appropriate. Values of  $p < 0.05$  were considered statistically significant.

## RESULTS

**Allosteric effects of 2A3BTs on both orthosteric agonist and antagonist binding are quantitatively consistent with interaction via a common extracellular allosteric site on the A<sub>1</sub> receptor.**

Mechanistic studies of allosteric modulator effects on orthosteric radiolabeled agonist at A<sub>1</sub> receptors have only been performed on broken cell preparations; this likely reflects the fact that a) commercially available agonists of the A<sub>1</sub> receptor only display high affinity as radioligands when interacting with the G protein-coupled state of the receptor, which often be detected in whole cells, and b) agonists can promote receptor internalization in intact cells, which would confound interpretation of binding results. We thus first investigated the effects of T62 and our two novel derivatives, VCP520 and VCP333, on the equilibrium binding of the radiolabeled agonist [<sup>3</sup>H]CCPA (2nM) in FlpIn-CHO A<sub>1</sub> receptor membranes (Figure 2A). As expected, the orthosteric agonist, *R*-PIA, completely inhibited [<sup>3</sup>H]CCPA binding at the A<sub>1</sub> receptor, characterized by a Hill coefficient not significantly different from 1 ( $n_H = 0.98 \pm 0.04$ ) and preferentially fitted to a one-site competition binding model ( $pK_I = 8.68 \pm 0.01$  for the high affinity state;  $n=3$ ). In contrast, all three allosteric ligands caused variable degrees of enhancement of the binding of [<sup>3</sup>H]CCPA, ranging from around 10% above control specific binding with VCP333 to around 50% with VCP520. However, concentrations higher than 10  $\mu$ M resulted in a reduction of specific radioligand binding, as expected based on prior studies of 2A3BTs. To quantify the degree of potentiation, therefore, the data points up to the effect of 10  $\mu$ M of modulator were fitted to an allosteric ternary complex model (Christopoulos and Kenakin, 2002; May et al., 2007b) and the results are shown in Table 1, where it can be seen that all three modulators displayed similar

**MOL #64568**

affinities ( $pK_B$ ) for the allosteric site on the unoccupied  $A_1$  receptor, but different degrees of cooperativity ( $\alpha$ ) when the receptor is occupied by [ $^3H$ ]CCPA.

To further validate the results of our analysis, we investigated the effect of the allosteric modulators on the rate of [ $^3H$ ]CCPA dissociation from receptors that had been pre-equilibrated with the radioligand. In theory, the potency ( $EC_{50}$ ) of an allosteric modulator to affect the rate of dissociation of an orthosteric ligand should equal the ratio of the affinity constant of the modulator for the receptor ( $K_B$ ) divided by the cooperativity factor ( $\alpha$ ) for the interaction (Kostenis and Mohr, 1996; Lazareno and Birdsall, 1995), provided that the radioligand dissociation was monophasic both in the absence and presence of modulator; the latter property was confirmed in control experiments where we tested the effects of a single concentration (3 $\mu$ M) of each modulator for effects on the control [ $^3H$ ]CCPA dissociation rate ( $k_{off} = 0.042 \pm 0.006$ ;  $n = 3$ ) at the  $A_1$  receptor in a full time course assay (data not shown). We thus constructed complete concentration-response curves for the inhibition of [ $^3H$ ]CCPA dissociation at the  $A_1$  receptor with all three ligands (3nM - 10 $\mu$ M) using a “two-point dissociation kinetic paradigm (Figure 2B). The estimated potencies ( $pEC_{50}$ ) for this effect were determined as: T62,  $5.94 \pm 0.10$  ( $n=3$ ); VCP520,  $6.92 \pm 0.11$  ( $n=3$ ); VCP333,  $5.61 \pm 0.18$  ( $n=3$ ). These values showed excellent concordance with theoretical predictions based on the sum of the  $pK_B$  and  $\log \alpha$  estimates from Table 1, namely, 6.13, 6.73 and 5.68 for T62, VCP520 and VCP333, respectively. Interestingly, however, the maximal effect on agonist dissociation observed at the highest concentrations of allosteric modulator trended towards a plateau greater than 0%, which was most evident for VCP520.

We next studied the effects of *R*-PIA and the three allosteric modulators on the equilibrium binding of two different concentrations of the orthosteric antagonist, [ $^3H$ ]DPCPX (1nM,

## MOL #64568

approx.  $1 \times K_A$  and 5 nM, approx.  $5 \times K_A$ ; Figure 3A). In both instances, *R*-PIA completely inhibited the specific binding of the radioligand. For the experiments performed against 1 nM [ $^3$ H]DPCPX, the *R*-PIA Hill coefficient was  $0.99 \pm 0.05$ , and its estimated  $pK_I$  value was  $6.33 \pm 0.04$ ; for the experiments performed against 5 nM [ $^3$ H]DPCPX, the *R*-PIA Hill coefficient was  $0.91 \pm 0.04$ , and its estimated  $pK_I$  value was  $6.73 \pm 0.02$  ( $n = 3$ ). The  $pK_I$  values were significantly different ( $p < 0.05$ ) from that determined against [ $^3$ H]CCPA, suggesting that the interaction between *R*-PIA and [ $^3$ H]DPCPX (Figure 3A) was preferentially reflecting binding to the low affinity (G protein-uncoupled) state of the  $A_1$  receptor. Each of the allosteric modulators also inhibited the binding of [ $^3$ H]DPCPX, in contrast to their effects on agonist binding. Although the inhibition of 1 nM [ $^3$ H]DPCPX binding mediated by VCP520 and VCP333 was incomplete, consistent with an allosteric interaction characterized by limited negative cooperativity, the inhibition mediated by T62 appeared complete and may be reconciled with a competitive mechanism. However, when these experiments were repeated against a higher concentration of [ $^3$ H]DPCPX (5 nM), the allosteric nature of the interaction was readily evident in the behavior of all three ligands, as the inhibition of radioligand binding in each modulator approached a limit over which no further inhibition of specific binding was attainable. Application of an allosteric ternary complex model to the data yielded the parameters shown in Table 1. Of particular importance was the fact that the  $pK_B$  estimates for each of the modulators were not significantly different ( $p > 0.05$ ) when determined using [ $^3$ H]DPCPX as the orthosteric ligand relative to when [ $^3$ H]CCPA was used as the orthosteric ligand. This indicates that, in each instance, the modulators recognize a common allosteric site on the unoccupied receptor with similar affinity irrespective of whether the interaction is probed using an agonist versus an antagonist orthosteric ligand. However, the nature and magnitude of the cooperativity between the two types of ligands is drastically altered depending on the orthosteric probe

## MOL #64568

(agonist vs antagonist). This phenomenon is a hallmark of GPCR allosteric modulation, and is referred to as “probe dependence” (Kenakin, 2009; Leach et al., 2007).

To confirm that the interaction between [<sup>3</sup>H]DPCPX (1 nM) and the modulators was mediated by an extracellular allosteric site, the experiments were repeated using intact FlpIn-CHO A<sub>1</sub> receptor cells, but otherwise identical assay conditions as the membrane-based assays with respect to buffer, temperature and incubation time (Figure 3B). As with the experiments performed in membranes, *R*-PIA caused a complete inhibition of radioligand binding ( $pK_I = 6.69 \pm 0.03$ ;  $n=3$ ). In contrast, all three allosteric modulators caused a saturable but incomplete inhibition of [<sup>3</sup>H]DPCPX specific binding, unambiguously indicating an allosteric mode of action. Moreover, the  $pK_B$  and values derived from the whole cell binding using the ATCM were not significantly different from the values derived from the membrane-based studies (Table 1). A slight discrepancy was noted in the estimates of negative cooperativity for VCP520 and VCP333 between the membrane vs intact cell experiments, but this only reached statistical significance for the case of VCP333; even in the latter instance, the overall cooperativity estimates were in the same range (i.e., approx.  $\alpha = 0.1$  vs 0.3). Overall, the results of our binding assays indicate, for the first time, that the potentiation component of orthosteric agonist binding isotherms determined in membranes, as well as the inhibition of antagonist affinity in both membranes and intact cells by 2A3BTs, can be quantitatively accommodated by interaction with a common extracellular allosteric site on the A<sub>1</sub> receptor.

### **2A3BTs display functional selectivity as allosteric agonists of A<sub>1</sub> receptor function**

Given that the 2A3BTs selectively potentiated agonist binding to the high affinity, presumably G protein-coupled, state of the A<sub>1</sub> receptor, we investigated whether the



## MOL #64568

compounds on their own can promote receptor activation, and whether the nature of this activation differed relative to the prototypical orthosteric agonist, *R*-PIA. For this purpose, four different assays of A<sub>1</sub> receptor activation were utilized, namely, ERK1/2 phosphorylation, inhibition of forskolin-stimulate cAMP accumulation, mobilization of intracellular Ca<sup>2+</sup>, and promotion of [<sup>35</sup>S]GTPγS binding to activated Gα<sub>i/o</sub> proteins. The results of these studies are summarized in Figure 4, where a number of interesting observations were made. First, with the exception of intracellular Ca<sup>2+</sup> mobilization, all allosteric ligands were able to mediate changes in receptor activity in their own right. Second, when compared to *R*-PIA, all three allosteric ligands displayed divergent concentration-response relationships for promoting [<sup>35</sup>S]GTPγS binding (Figure 4E), with T62 and VCP520 characterized by both stimulatory and inhibitory effects while VCP333 only showed inhibitory effects on basal G protein activation. Third, when considering the stimulatory components of signaling of the four ligands across the various pathways, it was noted that the rank order of potencies for phosphorylation of ERK1/2 relative to inhibition of cAMP and promotion of [<sup>35</sup>S]GTPγS binding were reversed for VCP520 and T62 relative to the orthosteric agonist, *R*-PIA; this is more evident in Figure 4F, where the percent response for equivalent concentrations of each ligand at the cAMP and ERK1/2 assays were graphed against each other in the form of a “bias plot” (Gregory et al. 2010). This finding is a hallmark of functional selectivity and suggests that the allosteric ligands bias the receptor stimulus in a manner that is different to the orthosteric agonist.

### **2A3BTs are positive allosteric modulators of *R*-PIA in whole cell functional assays**

The functional assays suggested differences in the manifestation of compound effects depending on whether receptor function was probed in whole cells versus membranes. Thus, we next focused on the ability of the 2A3BTs to modulate the function of an orthosteric

## MOL #64568

agonist at the A<sub>1</sub> receptor in intact FlpIn-CHO cells by performing interaction studies between each modulator and *R*-PIA in the ERK1/2 phosphorylation, inhibition of cAMP accumulation and intracellular Ca<sup>2+</sup> mobilization assays (Figure 5). In all instances, each allosteric ligand acted as a potentiator of *R*-PIA function, although the extent and manifestation of the positive modulation varied with the pathway. For ERK1/2 phosphorylation and cAMP inhibition, where *R*-PIA was a full agonist, the allosteric effect of the 2A3BTs was manifested as an increase in the potency of *R*-PIA (Figure 5A-F). For intracellular Ca<sup>2+</sup> mobilization, the modulation was manifested primarily as an increase in the maximal *R*-PIA response (Figure 5G-I); this finding suggests that *R*-PIA was not behaving as a full agonist in this assay, and is consistent with the notion that the coupling of the A<sub>1</sub> receptor to intracellular Ca<sup>2+</sup> mobilization is less efficient than its coupling to the other pathways. By applying an operational model of agonism (Equations 1 and 2) to the entire set of curves (Figure 5A – I), we were able to quantify the allosteric interaction for each modulator at each of the pathways. The results of this analysis are summarized in Table 2, where it can be seen that the functional estimates of modulator affinity were in general agreement with those obtained from the binding assays performed on whole cells (vs [<sup>3</sup>H]DPCPX, Table 1). Interestingly, the magnitude of positive cooperativity, quantified by the composite  $\alpha\beta$  parameter in our operational model, appeared to vary between some pathways. In particular, the potentiation of *R*-PIA function by VCP520 in the Ca<sup>2+</sup> mobilization was significantly greater (one-way ANOVA,  $p < 0.05$ ) than that noted for ERK1/2 phosphorylation. This suggests that the allosteric modulators may also engender functional selectivity in the actions of orthosteric ligands acting at the A<sub>1</sub> receptor.

### 2A3BTs display divergent effects on allosteric modulation of G protein activation in broken cell preparations

## MOL #64568

Functional interaction studies between *R*-PIA and each of the 2A3BTs were then extended to the [<sup>35</sup>S]GTPγS binding assay in membranes of A<sub>1</sub> receptor FlpIn-CHO cells (Figure 6). For these experiments, only concentrations up to 3 μM of modulator were utilized, where it can be seen that both T62 and VCP520 caused an increase in the basal response and the potency of *R*-PIA (Figure 6A, B). Application of our operational model of allosterism (Equation 2) to the data yielded  $pK_B = 6.02 \pm 0.09$  and  $\text{Log}\alpha\beta = 0.46 \pm 0.06$  ( $n = 3$ ) for T62, and  $pK_B = 5.96 \pm 0.11$  and  $\text{Log}\alpha\beta = 1.19 \pm 0.14$  ( $n = 3$ ) for VCP520. However, VCP333 caused a concentration-dependent *decrease* in the maximal response to the orthosteric agonist, with no significant effect on agonist potency (*R*-PIA  $pEC_{50} = 8.21 \pm 0.06$  in the absence of modulator, and  $8.31 \pm 0.19$  in the presence of 3 μM VCP333; Figure 6C). Together with the findings obtained when these compounds were tested alone over a higher concentration range (Figure 4E), our results suggest that the 2A3BTs actually bind to two different sites with, presumably, different structure-activity requirements. Furthermore, given the results of our studies on whole cells, it is likely that the second site of action is not the orthosteric site, but rather an intracellular binding site.

### 2A3BTs are direct G protein inhibitors

To determine whether the G protein inhibitory effect of the 2A3BTs is specific to the A<sub>1</sub> receptor or whether it occurs directly at the level of the G protein, we investigated their ability to inhibit [<sup>35</sup>S]GTPγS binding promoted by another G<sub>i/o</sub>-coupled receptor, the M<sub>2</sub> mAChR. Furthermore, we extended our studies to include the effects of two other well-characterized 2A3BT allosteric modulators of the A<sub>1</sub> receptor, LUF5484 and PD81,723 (Figure 1), in order to determine whether this property is common to 2A3BTs as a class. As shown in Figures 7A-E, all 5 allosteric ligands inhibited carbachol (100μM)-stimulated [<sup>35</sup>S]GTPγS binding in a concentration-dependent manner and with similar potencies (Table

# **MOL #64568**

3). Interestingly, the 2A3BTs also reduced [<sup>35</sup>S]GTPγS binding in the presence of a saturating concentration of the inverse agonist, atropine (10 μM), suggesting that their effect is directly on the G protein, rather than the receptor. We also repeated these experiments using T62, VCP520 or VCP333 at the A<sub>1</sub> receptor in the presence of a saturating concentration (10 μM) of the antagonist, DPCPX. As shown in Figures 7F-H, a modest inhibition of activity was noted for T62 and VCP333, but not for VCP520; this finding reflects the fact that, at this receptor, the ligands can also display variable degrees of direct receptor activation via the allosteric site, which is most pronounced with VCP520 (Fig. 4E) and, thus, the observed response profile in the presence of DPCPX will reflect a composite of both stimulatory and inhibitory actions on G protein activity. Importantly, we also noted a reduction in basal [<sup>35</sup>S]GTPγS binding to the 2A3BTs observed in non-transfected FlpIn-CHO cells (Supplementary Fig. 1), confirming that this inhibitory effect is receptor-independent. Although the mechanism underlying the direct inhibitory effect of the 2A3BTs on G protein activity is unknown, we considered whether they promote receptor-G protein uncoupling in a manner akin to that of guanine nucleotides; which could account for their inhibitory effects on A<sub>1</sub> receptor agonist binding. To further test this, we monitored the effects of the 2A3BTs on the ability of ACh to compete with the antagonist, [<sup>3</sup>H]NMS, at the M<sub>2</sub> mAChR in FlpIn-CHO cell membranes. To our surprise, we found that the 2A3BTs had either no effect (VCP333, VCP520) or a modest enhancing effect (T62) on the ability of ACh to compete for [<sup>3</sup>H]NMS binding; an inhibition of [<sup>3</sup>H]NMS binding was also noted for VCP333 and T62 (Supplementary Fig. 2). In contrast, the addition of GppNHp (100 μM) yielded the anticipated result of a reduction in the affinity of ACh (Supplementary Fig. 2). Thus, the results of these experiments confirm that 2A3BTs, as a class, possess at least two modes of action, one via an extracellular allosteric site on the A<sub>1</sub> receptor and the other via an

## MOL #64568

intracellular (non-receptor) site on, or associated with,  $G_{i/o}$  family proteins that is not of the same mechanism as that exhibited by guanine nucleotides.

### **2A3BTs retain allosteric enhancing activity in a native tissue preparation**

Given our findings, an important consideration in the pursuit of 2A3BTs as allosteric modulators of  $A_1$  receptor function in a therapeutic setting is the extent to which the secondary, inhibitory, effects of such compounds can potentially compromise their utility as enhancers of adenosine activity in native tissues. To assess this in a physiologically relevant setting, we determined the effects of T62, VCP520 and VCP333 on *R*-PIA-mediated decrease in heart rate. Figure 8 shows that each allosteric ligand was able to promote a concentration-dependent increase in the effect of an  $EC_{10}$  concentration of agonist. Unfortunately, solubility limitations precluded our ability to test higher concentrations of modulators in the organ bath.

## MOL #64568

### DISCUSSION

After nearly two decades of research, the prevailing view on the mechanism of action of 2A3BTs at the adenosine A<sub>1</sub> receptor invokes interaction with both an allosteric and the orthosteric site. In turn, this has led to many structure-activity studies aimed at removing the apparently competitive properties of 2A3BTs while retaining allosteric properties (see Introduction). Our study now shows that this mechanism is unlikely to be correct and that the pharmacology of 2A3BTs arises from binding to an extracellular allosteric site, which can quantitatively accommodate different interactions with agonists versus antagonists, and, depending on accessibility, another interaction with an intracellular site(s) specifically involved in G protein activity. In addition, we have also shown that 2A3BTs can display functional selectivity, mediated via this allosteric site, in their ability to recruit signaling pathways relative to a prototypical orthosteric agonist.

The detection of allosteric effects at GPCRs requires careful consideration of the signal-to-noise window because of the phenomenon of cooperativity between orthosteric and allosteric sites (May et al., 2007b). On the one hand, weak positive or negative cooperativity can lead to a failure to detect an allosteric interaction. On the other hand, strong negative cooperativity can be difficult to distinguish from competition. As we have now demonstrated, the interaction between 2A3BTs and the orthosteric antagonist, [<sup>3</sup>H]DPCPX, can be quantitatively accommodated by a simple ATCM characterized by negative cooperativity between the orthosteric probe and each of the allosteric ligands, but for T62 at least, the negative cooperativity is high enough when determined in membrane-based assays using an approx. K<sub>A</sub> concentration of orthosteric radioligand as to appear consistent with a competitive effect. Because many published studies of A<sub>1</sub> receptor radioligand binding have

**MOL #64568**

been performed in membrane preparations, it is perhaps not surprising that negative allosteric interactions have been mis-classified as competitive. To our knowledge, only one prior study (Figler et al., 2003) has suggested that the interaction between 2A3BTs and an antagonist ( $[^3\text{H}]\text{DCPX}$ ) may be allosteric. Application of the ATCM in our study has allowed for the determination of the affinity of each of the modulators for the allosteric site on the  $\text{A}_1$  receptor, as well as the cooperativity factors governing the interaction with  $[^3\text{H}]\text{DPCPX}$  (Table 1). Importantly, the affinity values were not significantly different from those obtained when performing the same interaction in whole cells, nor when using  $[^3\text{H}]\text{CCPA}$  as an agonist probe of the interaction in membranes. These findings suggest that the ATCM is an appropriate mechanistic descriptor of the interaction because, according to the model, the  $\text{pK}_\text{B}$  parameter is a measure of the affinity of the modulator for the unoccupied receptor and is thus independent of the nature of the orthosteric probe (Leach et al., 2007). Our findings using the intact cell binding assay also suggest that the 2A3BT allosteric site is located extracellularly.

In contrast, differences were noted in the cooperativity of the interaction depending on the orthosteric ligand that was used. This phenomenon, termed “probe dependence”, is a hallmark of allosterism at GPCRs (Kenakin, 2009; Leach et al., 2007; May et al., 2007b), and indicates that allosteric ligands either sense and/or promote different receptor conformations depending on the orthosteric partner. In our case, the 2A3BTs prefer to bind to the allosteric site of an agonist-occupied receptor. At higher concentrations of modulator, in membrane-based assays, the secondary G protein inhibitory effect that we identified results in a loss of agonist binding, which we observed in the  $[^3\text{H}]\text{CCPA}$  experiments (Fig. 2A). This dual mechanism can thus account for the complex behavior of 2A3BTs noted in the past. Interestingly, this same mechanism may also account for the inability of high concentrations

**MOL #64568**

of 2A3BTs (especially VCP520) to completely prevent [ $^3$ H]CCPA dissociation (Fig. 2B); the slowing of dissociation promoted by action at an extracellular allosteric site on the A<sub>1</sub> receptor may be offset by an increase in dissociation promoted by intracellular actions of the 2A3BT, yielding a net effect of submaximal inhibition of radioligand dissociation.

A consideration of the effects of 2A3BTs arising solely from interaction with an extracellular allosteric site on the A<sub>1</sub> receptor leads to a number of interesting conclusions. The first is that these compounds can behave as agonists of the receptor in their own right, as evidenced in whole cell assays of ERK1/2 phosphorylation and cAMP accumulation; the lack of effect on calcium mobilization most likely reflects the poor coupling of this latter pathway to A<sub>1</sub> receptor activation. The finding of direct allosteric agonism with 2A3BTs has been noted previously (Aurelio et al., 2009; Baraldi et al., 2000; Bhattacharya and Linden, 1995; Bruns and Fergus, 1990; Bruns et al., 1990; Figler et al., 2003; Musser et al., 1999), suggesting that their mechanism of allosteric potentiation likely involves, at least in part, an increase in the proportion of receptors in an active state and, hence, an increase in receptor-G protein coupling (Bhattacharya and Linden, 1995; Bruns and Fergus, 1990; Hall, 2000). However, a key novel finding in our current study was the reversal in potency orders of the 2-A3BTs and *R*-PIA for signaling to ERK1/2 relative to cAMP inhibition (Fig. 4), which suggests that the active conformation promoted by the allosteric ligands is not the same as that promoted by orthosteric agonists like *R*-PIA. This finding is a striking example of functional selectivity (Urban et al., 2007) and has significant implications for pathway-selective drug discovery. Importantly, our finding is also the first example of agonist functional selectivity arising solely from interaction with an allosteric site. It is likely that more such examples will be identified in the near future given the current focus on novel small molecule agonists in GPCR drug discovery programs.



**MOL #64568**

A second important observation on the allosteric properties of the 2A3BTs relates to their ability to act as allosteric potentiators of orthosteric agonist function. Application of our operational model of allosterism and agonism revealed that, in whole cells, the magnitude of the positive modulation of *R*-PIA function could vary between pathways, especially for VCP520 (Table 2). Based on the conformational hypothesis of 2A3BT action discussed in the preceding paragraph, it may be expected that the degree of positive allosteric enhancement should correlate with the degree of allosteric agonism displayed by the modulators, but this does not appear to be the case. Indeed, VCP520 promoted greater allosteric potentiation at the pathway for which it displayed no signaling efficacy. Therefore, this is an example of allosteric modulator-engendered functional selectivity in the actions of an orthosteric ligand, and highlights an additional means by which allosteric ligands can be used to further “fine-tune” orthosteric ligand responses (Leach et al., 2007).

With regards to the intracellular component of 2A3BT action, namely the ability to directly inhibit G protein function, it was noteworthy that the potency of the compounds to mediate this effect is similar to their affinity for the allosteric site (in the absence of orthosteric ligand). This has important implications in terms of structure-activity studies. First, our findings in intact CHO cells suggest that the compounds are unlikely to gain appreciable intracellular penetrance. However, this may not always be guaranteed, and thus the ideal aim of future structure-activity work would be to obtain as large a separation as possible between affinity for the allosteric site relative to G protein inhibitory activity. Second, depending on the nature of the assay, the observed response will reflect an interplay between the two properties (allosteric modulation and G protein inhibition); for a compound like VCP333, which is the weakest allosteric potentiator in our series based on the intact cell functional data

## MOL #64568

(Fig. 5), the resultant pharmacology would be in favor of inhibition, which explains why the compound appeared to inhibit [<sup>35</sup>S]GTPγS turnover at all concentrations tested. Third, we cannot conclude from our data whether the mechanism of G protein inhibition occurs directly at the level of the G protein itself, as opposed to another membrane component; certainly, the discrepant findings between effects on A<sub>1</sub> receptor agonist binding (Fig. 2) and M<sub>2</sub> mAChR agonist binding (Supplementary Fig.2) suggest that 2A3BTs do not act as simple receptor-G protein “uncouplers”, unlike guanine nucleotides such as GppNHp. However, it is nonetheless possible that 2A3BTs may prove to be novel scaffolds for the development of small molecule G protein inhibitors.

In conclusion, this study has identified the mechanisms underlying the complex mode of action of 2A3BTs as allosteric modulators of A<sub>1</sub> receptors and non-specific G protein inhibitors. Moreover, we have demonstrated how the A<sub>1</sub> receptor-specific effects of the compounds against both agonist and antagonist orthosteric ligands can be quantitatively accommodated by a simple ternary complex model. Finally, we have identified novel functional selectivity in the actions of 2A3BTs both as allosteric agonists and allosteric modulators.

## ACKNOWLEDGMENTS

The authors are grateful to Drs Michael Crouch and Ron Osmond, TGR Biosciences, Australia, for the generous gift of ERK1/2 *SureFire* kit reagents.

## REFERENCES

- Aurelio L, Figler H, Flynn BL, Linden J and Scammells PJ (2008) 5-Substituted 2-aminothiophenes as A1 adenosine receptor allosteric enhancers. *Bioorg Med Chem* **16**(3):1319-1327.
- Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. *J Med Chem* **52**(14):4543-4547.
- Baraldi PG, Iaconinoto MA, Moorman AR, Carrion MD, Cara CL, Preti D, Lopez OC, Fruttarolo F, Tabrizi MA and Romagnoli R (2007) Allosteric enhancers for A1 adenosine receptor. *Mini Rev Med Chem* **7**(6):559-569.
- Baraldi PG, Pavani MG, Leung E, Moorman AR, Varani K, Vincenzi F, Borea PA and Romagnoli R (2006) Synthesis and biological characterization of [3H] (2-amino-4,5,6,7-tetrahydrobenzo[*b*]thiophen-3-yl)-(4-chlorophenyl)-methanone, the first radiolabelled adenosine A1 allosteric enhancer. *Bioorg Med Chem Lett* **16**(5):1402-1404.
- Baraldi PG, Zaid AN, Lampronti I, Fruttarolo F, Pavani MG, Tabrizi MA, Shryock JC, Leung E and Romagnoli R (2000) Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. *Bioorg Med Chem Lett* **10**(17):1953-1957.
- Bhattacharya S and Linden J (1995) The allosteric enhancer, PD 81,723, stabilizes human A1 adenosine receptor coupling to G proteins. *Biochim Biophys Acta* **1265**(1):15-21.
- Bruns RF and Fergus JH (1990) Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. *Mol Pharmacol* **38**(6):939-949.

**MOL #64568**

- Bruns RF, Fergus JH, Coughenour LL, Courtland GG, Pugsley TA, Dodd JH and Tinney FJ (1990) Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. *Mol Pharmacol* **38**(6):950-958.
- Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. *Biochem Pharmacol* **22**(23):3099-3108.
- Childers SR, Li X, Xiao R and Eisenach JC (2005) Allosteric modulation of adenosine A1 receptor coupling to G-proteins in brain. *J Neurochem* **93**(3):715-723.
- Christopoulos A (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. *Trends Pharmacol Sci* **19**(9):351-357.
- Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. *Nat Rev Drug Discov* **1**(3):198-210.
- Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. *Pharmacol Rev* **54**(2):323-374.
- Conn PJ, Christopoulos A and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. *Nat Rev Drug Discov* **8**(1):41-54.
- Elzein E and Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. *Expert Opin Investig Drugs* **17**(12):1901-1910.
- Ferguson GN, Valant C, Horne J, Figler H, Flynn BL, Linden J, Chalmers DK, Sexton PM, Christopoulos A and Scammells PJ (2008) 2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. *J Med Chem* **51**(19):6165-6172.
- Figler H, Olsson RA and Linden J (2003) Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. *Mol Pharmacol* **64**(6):1557-1564.

**MOL #64568**

- Gao ZG and Jacobson KA (2007) Emerging adenosine receptor agonists. *Expert Opin Emerg Drugs* **12**(3):479-492.
- Gregory KJ, Hall NE, Tobin AB, Sexton PM and Christopoulos (2010) A Identification of orthosteric and allosteric site mutations in M<sub>2</sub> muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. *J Biol Chem.*, **285**: 7459-7474.
- Hall DA (2000) Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. *Mol Pharmacol* **58**(6):1412-1423.
- Kenakin TP (2009) 7TM receptor allostery: putting numbers to shapeshifting proteins. *Trends Pharmacol Sci* **30**(9):460-469.
- Kostenis E and Mohr K (1996) Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. *Trends Pharmacol Sci* **17**(8):280-283.
- Lagerstrom MC and Schioth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. *Nat Rev Drug Discov* **7**(4):339-357.
- Latini S, Bordoni F, Pedata F and Corradetti R (1999) Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. *Br J Pharmacol* **127**(3):729-739.
- Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. *Mol Pharmacol* **48**(2):362-378.
- Leach K, Sexton PM and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. *Trends Pharmacol Sci* **28**(8):382-389.

**MOL #64568**

- Lutjens H, Zickgraf A, Figler H, Linden J, Olsson RA and Scammells PJ (2003) 2-Amino-3-benzoylthiophene allosteric enhancers of A1 adenosine agonist binding: new 3, 4-, and 5-modifications. *J Med Chem* **46**(10):1870-1877.
- May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM and Christopoulos A (2007a) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. *Mol Pharmacol* **72**(2):463-476.
- May LT, Leach K, Sexton PM and Christopoulos A (2007b) Allosteric modulation of G protein-coupled receptors. *Annu Rev Pharmacol Toxicol* **47**:1-51.
- May LT, Sexton PM and Christopoulos A (2005) Effects of urea pretreatment on the binding properties of adenosine A1 receptors. *Br J Pharmacol* **146**(8):1119-1129.
- Musser B, Mudumbi RV, Liu J, Olson RD and Vestal RE (1999) Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. *J Pharmacol Exp Ther* **288**(2):446-454.
- Nakanishi M, Tahara T, Araki K, Shiroki M and Tsumagari T (1973) Studies on psychotropic drugs. 18. Synthesis and structure-activity relationships of 5-phenyl-1,3-dihydro-2H-thieno(2,3-e) (1,4) diazepin-2-ones. *J Med Chem* **16**(3):214-219.
- Nikolakopoulos G, Figler H, Linden J and Scammells PJ (2006) 2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. *Bioorg Med Chem* **14**(7):2358-2365.
- Overington JP, Al-Lazikani B and Hopkins AL (2006) How many drug targets are there? *Nat Rev Drug Discov* **5**(12):993-996.
- Rudolphi KA, Schubert P, Parkinson FE and Fredholm BB (1992) Neuroprotective role of adenosine in cerebral ischaemia. *Trends Pharmacol Sci* **13**(12):439-445.
- Stewart GD, Valant C, Dowell SJ, Mijaljica D, Devenish RJ, Scammells PJ, Sexton PM and Christopoulos A (2009) Determination of adenosine A1 receptor agonist and

**MOL #64568**

antagonist pharmacology using *Saccharomyces cerevisiae*: implications for ligand screening and functional selectivity. *J Pharmacol Exp Ther* **331**(1):277-286.

Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M and Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. *J Pharmacol Exp Ther* **320**(1):1-13.

van der Klein PA, Kourounakis AP and AP IJ (1999) Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. *J Med Chem* **42**(18):3629-3635.

**MOL #64568**

**FOOTNOTES**

This work was funded by the National Health and Medical Research Council (NHMRC) of Australia, Program Grant No. [519461], and the Australian Research Council, Discovery Grant No. [DP0877497]. AC is a Senior, and PMS a Principal, Research Fellow of the NHMRC.



## FIGURE LEGENDS

**Figure 1. Structures of 2-amino-3-benzoylthiophene (2A3BT) derivatives used in this study.**

**Figure 2. 2A3BTs have divergent effects on orthosteric agonist binding.** (A) Effects of the orthosteric agonist, *R*-PIA, or the allosteric modulators T62, VCP520, or VCP333 on the binding of [<sup>3</sup>H]CCPA at A<sub>1</sub> receptors expressed in FlpIn-CHO membranes. Data points represent the mean ± S.E. obtained from three experiments conducted in duplicate. Curves drawn through the datapoints represent the best fit of a competitive (*R*-PIA) or allosteric ternary complex model (T63, VCP52, VCP333). (B) Effects of the allosteric modulators on the apparent dissociation rate of [<sup>3</sup>H]CCPA from A<sub>1</sub> receptors expressed in FlpIn-CHO membranes. Data were normalized to the percentage of the control rate constant determined in absence of modulator, and represent the mean ± S.E. obtained from three experiments conducted in triplicate.

**Figure 3. 2A3BTs are negative allosteric modulators of orthosteric antagonist binding.** Effects of the orthosteric agonist, *R*-PIA, or the allosteric modulators T62, VCP520, or VCP333 on the binding of [<sup>3</sup>H]DPCPX at A<sub>1</sub> receptors expressed in FlpIn-CHO membranes (A) or intact cells (B). Data points represent the mean ± S.E. obtained from three experiments conducted in duplicate. Curves drawn through the datapoints represent the best fit of a competitive (*R*-PIA) or allosteric ternary complex model (T63, VCP52, VCP333).

**Figure 4. 2A3BTs display functional selectivity as allosteric agonists of the A<sub>1</sub> receptor.** (A-D) Effects of the indicated agonist on A<sub>1</sub>-mediated ERK1/2 phosphorylation, inhibition of

## MOL #64568

forskolin-stimulated cAMP accumulation and intracellular calcium mobilization in intact FlpIn-CHO cells. (E) Effects of the indicated agonist on A<sub>1</sub>-mediated [<sup>35</sup>S]GTPγS binding to activated G proteins in FlpIn-CHO membranes. In all instances, data points represent the mean ± S.E. obtained from three to four experiments conducted in duplicate. (E) “Bias plot”, showing the nonlinear curve fits from panels A-D for cAMP and ERK1/2 responses plotted against each other.

**Figure 5. Different degrees of positive allosteric modulation of *R*-PIA function by 2A3BTs in intact cells.** Effects of T62 (A, D, G), VCP520 (B, E,H) or VCP333 (C, F, I) on *R*-PIA-mediated ERK1/2 phosphorylation (A-C), cAMP inhibition (D-F) or intracellular calcium mobilization (G-I). Data points represent the mean ± S.E. obtained from three to five experiments conducted in duplicate. Curves drawn through the data represent the best global fit of an operational model of allosterism to all 9 datasets (Table 2).

**Figure 6. 2A3BTs have divergent effects on orthosteric agonist function in a broken cell preparation.** Effects of T62 (A), VCP520 (B) and VCP333 (C) on *R*-PIA-mediated [<sup>35</sup>S]GTPγS binding to activated G proteins in membranes prepared from FlpIn-CHO cells stably expressing the A<sub>1</sub> receptor. Data points represent the mean ± S.E. obtained from three experiments conducted in duplicate and are normalized to 1μM *R*-PIA response. Curves drawn through the data in panels A and B represent the best fit to an operational model of allosterism.

**Figure 7. 2A3BTs are inhibitors of G<sub>i/o</sub> proteins.** Effect of LUF5484 (A), PD81,723 (B), T62 (C), VCP520 (D) or VCP333 (E) on M<sub>2</sub> mAChR-mediated [<sup>35</sup>S]GTPγS binding to activated G proteins in the presence or absence of the orthosteric agonist, carbachol 100μM

**MOL #64568**

(○), or orthosteric agonist, atropine (□)10μM, in FlpIn-CHO cells. Data points represent the mean ± S.E. obtained from four experiments conducted in duplicate and normalized to the fold-over basal. (F-G) Effect of the indicated modulator on A<sub>1</sub> receptor-mediated [<sup>35</sup>S]GTPγS binding to activated G proteins in the presence of the orthosteric antagonist, DPCPX. Data points represent the mean ± S.E. obtained from three experiments conducted in duplicate and normalized to the fold-over basal.

**Figure 8. 2A3BTs retain allosteric enhancement properties in intact native tissues.**

Effect of VCP333 (white bars), VCP520 (checked bars) and T62 (black bars) on *R*-PIA (10 nM)-mediated decrease in rate of contraction of rat right atrium. Data bars represent the mean ± S.E. obtained from four experiments conducted in duplicate and normalized to the maximum *R*-PIA response.

**TABLE 1** A<sub>1</sub> receptor binding (pK<sub>B</sub>) and cooperativity (log α) estimates of the allosteric modulators for interaction with orthosteric radioligands. Data are expressed as the mean ± S.E. of three separate experiments performed in duplicate.

	Membranes				Intact cells			
	<sup>3</sup> H]CCPA		<sup>3</sup> H]DPCPX (1 nM)		<sup>3</sup> H]DPCPX (5 nM)		<sup>3</sup> H]DPCPX	
	pK <sub>B</sub>	log α	pK <sub>B</sub>	log α	pK <sub>B</sub>	log α	pK <sub>B</sub>	log α
<b>T62</b>	5.69 ± 0.10	0.44 ± 0.03 (α = 2.8)	5.60 ± 0.07	-47 (α → 0)	5.74 ± 0.07	-1.10 ± 0.09 (α = 0.08)	5.68 ± 0.08	-0.91 ± 0.11 (α = 0.12)
<b>VCP520</b>	5.90 ± 0.20	0.83 ± 0.11 (α = 6.8)	5.91 ± 0.05	-0.72 ± 0.04 (α = 0.19)	6.25 ± 0.07	-0.72 ± 0.03 (α = 0.19)	5.77 ± 0.08	-0.49 ± 0.03 (α = 0.33)
<b>VCP333</b>	5.46 ± 0.34	0.22 ± 0.06 (α = 1.7)	5.66 ± 0.03	-0.97 ± 0.06 (α = 0.11)	5.99 ± 0.06	-0.92 ± 0.05 (α = 0.12)	5.64 ± 0.10	-0.49 ± 0.04 (α = 0.33)

**TABLE 2** Allosteric model parameters for the interaction between *R*-PIA and various allosteric modulators in cell-based assays.

	<b>pK<sub>B</sub><sup>a</sup></b>	<b>ERK 1/2 phosphorylation</b>		<b>cAMP</b>		<b>Ca<sup>2+</sup></b>	
		<b>log αβ<sup>b</sup></b>	<b>log τ<sup>c</sup></b>	<b>log αβ</b>	<b>log τ</b>	<b>log αβ</b>	<b>log τ</b>
<b>T62</b>	5.49 ± 0.09	0.58 ± 0.06 (αβ = 3.8)	-0.32 ± 0.05 (τ = 0.5)	0.77 ± 0.13 (αβ = 5.9)	0.08 ± 0.06 (τ = 1.2)	0.87 ± 0.08 (αβ = 7.4)	n.a. <sup>d</sup>
<b>VCP520</b>	5.64 ± 0.14	0.57 ± 0.11 (αβ = 3.7)	-0.48 ± 0.11 (τ = 0.3)	0.79 ± 0.07 (αβ = 6.2)	-0.18 ± 0.21 (τ = 0.7)	1.07 ± 0.09* (αβ = 11.7)	n.a.
<b>VCP333</b>	5.23 ± 0.25	0.64 ± 0.12 (αβ = 4.4)	-1.34 ± 0.75 (τ = 0.05)	0.91 ± 0.33 (αβ = 8.1)	0.10 ± 0.27 (τ = 1.3)	0.67 ± 0.13 (αβ = 4.7)	n.a.

<sup>a</sup> antilogarithm of the dissociation constant of the allosteric modulator.<sup>b</sup> logarithm of the composite cooperativity between the allosteric modulator and *R*-PIA.<sup>c</sup> logarithm of the operational efficacy of the allosteric modulator.<sup>d</sup> Not applicable. Log τ fixed to -1000 since τ = 0 (ligand lacks agonism for this pathway).

\*Statistically different (p &lt; 0.05) from the value for ERK1/2 phosphorylation, as determined by one-way ANOVA followed by Newman-Keuls test.

**MOL #64568**

**TABLE 3** Potency (pEC<sub>50</sub>) estimates for inhibition of G protein activity by 2-amino-3-benzoylthiophenes in [<sup>35</sup>S]GTPγS binding assay at the M<sub>2</sub> mAChR (n=4) and A<sub>1</sub> receptor (n=3).

	pEC <sub>50</sub>		
	M <sub>2</sub> mAChR		A <sub>1</sub> R
	+10μM Atropine	+100μM Carbachol	+10 μM DPCPX
<b>LUF5484</b>	5.33 ± 0.22	5.53 ± 0.06	n.d. <sup>a</sup>
<b>PD81,723</b>	4.98 ± 0.25	4.97 ± 0.07	n.d. <sup>a</sup>
<b>T62</b>	5.68 ± 0.26	5.60 ± 0.10	5.23 ± 0.08
<b>VCP520</b>	5.78 ± 0.21	5.78 ± 0.08	n.a. <sup>b</sup>
<b>VCP333</b>	5.77 ± 0.25	5.60 ± 0.07	5.67 ± 0.13

<sup>a</sup> Not determined

<sup>b</sup> Not applicable

**MOL #64568**




Figure 1






Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8